Wednesday , November 22 2017
Home / Psoriasis

Psoriasis

FDA Accepts Ortho Dermatologics’ NDA for IDP-118 for the Treatment of Plaque Psoriasis

LAVAL, Quebec, Nov. 2, 2017 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for …

Read More »

AbbVie’s Risankizumab Beats Humira and Stelara in Late-Stage Psoriasis Studies

NORTH CHICAGO, Ill., Oct. 26, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque …

Read More »

Janssen’s Simponi Aria Receives FDA Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Horsham, Pa., October 20, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab), the only fully-human anti-tumor necrosis factor (TNF)-alpha therapy administered via a 30-minute infusion, for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Today’s …

Read More »

Prothena Discontinues Development of PRX003 in Psoriasis Following Negative Trial Results

DUBLIN, Ireland, Sept. 28, 2017 (GLOBE NEWSWIRE) — Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced clinical results of a Phase 1b multiple ascending dose (MAD) study of PRX003 in patients with psoriasis. PRX003 is a …

Read More »

Novartis’ Cosentyx Sets New Benchmark in Psoriasis with Robust 5-Year Sustained Phase 3 Efficacy and Safety Data

Basel, September 13, 2017 – Novartis announced today, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, …

Read More »

Janssen’s Tremfya Receives FDA Approval for Treatment of Plaque Psoriasis

HORSHAM, Pa., July 13, 2017 /PRNewswire/ — Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved TREMFYA™ (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. TREMFYA™ is the first and …

Read More »

FDA Approves Bristol-Myers Squibb’s Orencia for Treatment of Active Psoriatic Arthritis

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved ORENCIA for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2, inflammatory disease that can affect both the skin and musculoskeletal system.3 ORENCIA is approved and available in both intravenous and subcutaneous (SC) …

Read More »

Lilly’s Taltz Significantly Improves Disease Signs and Symptoms in Psoriatic Arthritis Patients with Inadequate Response or Intolerance to TNF Inhibitors

altz INDIANAPOLIS, June 15, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz® (ixekizumab) achieved significant improvement in signs and symptoms of …

Read More »

Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clues

It’s one of the most common immune-mediated diseases in the U.S., causing red, patchy and scaly marks on the skin. Yet the 1 to 2 percent of the population who have psoriasis are still left to wonder why. A new study builds on the genetic architecture of psoriasis, the next …

Read More »

FDA Accepts for Review Pfizer’s sNDA for Xeljanz for Treatment of Patients with Active Psoriatic Arthritis

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) for the treatment of adult patients with active psoriatic arthritis (PsA). A separate sNDA was also …

Read More »